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Extracorporeal CO2 removal for stable 
hypercapnic COPD: is it really worth it?
Marieke L Duiverman  ,1 Peter J Wijkstra2
Long- term nocturnal non- invasive venti-
lation (NIV) is increasingly being applied 
in patients with chronic obstructive 
pulmonary disease (COPD) with chronic 
hypercapnic respiratory failure. Studies 
that have shown improvement in clinical 
and patient- related outcome measures 
have used a mode of ventilation aimed at 
a substantial reduction in carbon dioxide 
(CO2) levels.
1 Therefore, it might be 
suggested that CO2 reduction is a causal 
factor for improvement in clinical 
outcomes such as improvement in symp-
toms, health- related quality of life 
(HRQoL) and survival.
In line with this theory, in the linked 
paper, Pisani et al present a proof- of- 
concept study of extracorporeal CO2 
removal (ECCO2R) in patients with 
COPD with chronic hypercapnia unre-
sponsive to NIV.2 Although this tech-
nology has been investigated in patients 
with COPD with acute hypercapnic 
respiratory failure,3 the study of Pisani 
et al is the first study in stable patients 
with COPD with chronic hypercapnia. 
In this small study in 10 patients with 
COPD with variable COPD severity 
(FEV1 ranging from 18% to 55% of 
predicted) and persistent hypercapnia of 
varying degrees (arterial carbon dioxide 
tension (PaCO2) ranging from 51.7 to 
89.3 mm Hg), they showed that ECCO2R 
was safe. However, the planned 24 hours 
ECCO2R could only be completed in 6 
out of 10 patients. ECCO2R reduced 
PaCO2 by 23%–47% and, in the patients 
that completed the session, this sustained 
for 2–4 days following ECCO2R inter-
ruption. Although this is an interesting 
concept, probably providing an alter-
native for NIV in patients who do not 
benefit from NIV or experience severe 
side effects, important discussion points 
need to be raised.
First, what is the aim of treatment 
in advanced patients with COPD with 
chronic hypercapnic respiratory failure? 
If we ask our patients, they do not insist 
on substantial CO2 reduction; instead 
they would be helped by symptom reduc-
tion, improvement in HRQoL, exacerba-
tion reduction and improved survival. 
Moreover, the relationship between 
CO2 reduction and these patient- related 
outcomes is unclear and inconsistently 
shown in literature.4 Therefore, it is ques-
tionable whether with a therapy directed 
to CO2 reduction, similar or even better 
effects can be reached compared with 
a therapy that also influences sleep, 
sputum clearance, breathing patterns, 
ventilation- perfusion matching and lung 
function. Pisani et al do not provide any 
preliminary evidence of benefit in terms 
of patient related outcomes, which is a 
pity as, although it is a proof- of- concept 
study, patients would have been very 
well able to rate at least comfort and 
dyspnoea during and after ECCO2R.
We should not forget that ECCO2R 
is invasive and requires catheters to be 
inserted and 24 hours of ‘respiratory dial-
ysis’ on an experienced high care unit, 
which is not the preferred environment 
for chronic severely disabled patients. In 
fact, nocturnal NIV for chronic respira-
tory failure is increasingly being offered 
(initiated and followed) completely at 
home to confine with patient wishes, 
and relief the burden of increasing 
patient numbers placed on the healthcare 
system.5 In addition, the authors showed 
that in 4 out of 10 patients, ECCO2R 
could not be maintained for the planned 
24 hours due to different technical 
reasons. Conceptually, ‘CO2 dialysis’ can 
also be achieved by other means. Already 
15 years ago, Diaz et al showed that with 
intermittent daytime NIV, not only CO2 
levels, but also exercise capacity and 
dyspnoea improved substantially.6 Also, 
respiratory stimulant drugs, such as acet-
azolamide, can improve gas exchange . 
However, while inspiratory muscle effort 
is reduced by both NIV, that assists the 
respiratory muscles, and ECCO2R, with 
which less minute ventilation is spent to 
remove the produced CO2, with respira-
tory stimulant drugs, inspiratory muscle 
effort is expected to increase. In fact, 
studies on acetazolamide have shown 
improved oxygenation with a small fall 
in PaCO2 (3–7 mm Hg), but without 
positive (or even negative) effect on 
dyspnoea or HRQoL. Also, respiratory 
stimulant drugs are not effective or even 
harmful in patients with very severe 
COPD who simply cannot increase their 
ventilation, are not always well toler-
ated, and side effects might be serious 
and often unpredictable.7
Second, key to success, both for NIV 
and ECCO2R, is probably better patient 
selection. In COPD, it is hypothesised 
that chronic hypercapnia ensues once 
patients adopt a breathing pattern with 
low tidal volumes and high respira-
tory rate. Patients adopt this pattern to 
ensure that their respiratory muscles are 
not becoming fatigued in the context 
of detrimental respiratory mechanics.8 
However, chronic hypercapnia not 
always develops with advanced COPD 
or, the other way around, might develop 
in patients with relative mild lung func-
tion derangements. Especially in the 
more obese patients, we hypothesise 
that a combination of disordered lung 
mechanics and a reduced respiratory 
drive contribute to nocturnal hypoven-
tilation and the consecutive chronic 
daytime hypercapnia. ECCO2R would 
be most helpful in patients who need 
(only) resetting of their respiratory drive 
while having enough ventilatory capacity 
by themselves to change their breathing 
pattern during daytime. NIV would be 
more helpful if lung mechanics, sleep and 
sputum clearance needs to be supported 
too. In the paper of Pisani et al selec-
tion of patients was unfortunately not so 
specific, as they included patients based 
on daytime PaCO2 only. The inclusion 
criterion of less than 5% improvement 
of daytime CO2 with chronic NIV might 
reflect an inability of NIV to reduce CO2 
but might also be effective nocturnal NIV 
with a fast increase at daytime in severely 
ventilatory limited patients. Obviously, 
for this proof of concept study, a wide 
variety of patients with COPD, with 
probably different underlying patho-
physiology of chronic hypercapnia, was 
included.
To conclude, Pisani et al showed that 
ECCO2R is a safe treatment with effect 
on CO2 reduction. It would be exciting 
to see further studies with a carefully 
selected and characterised group of 
patients, preferably including measures 
of lung mechanics and ventilatory drive, 
investigating mechanisms of response 
and, most importantly, patient- related 
outcome measures, comparing it to 
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daytime or nocturnal NIV. Taking this 
into account, maybe in the future, with 
advances in the technology, ECCO2R 
would gain its place in a selected group 
of advanced stable COPD.
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